Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in St. Ingbert – page 16

306 clinical trials in St. Ingbert, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
St. Ingbert at a glance
306
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

306 trials in St. Ingbert

Open in trial search

Obesity

Not recruiting

A study to evaluate the efficacy and safety of zenagamtide in people with obesity

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Zenagamtide
  • Sponsor:Novo Nordisk A/S

Cervix carcinoma+1

Not recruiting

Sacituzumab Tirumotecan in Recurrent or Metastatic Cervical Cancer After Platinum Chemotherapy and Anti-PD-L1 or Anti-PD-1 Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate
  • Sponsor:Merck Sharp & Dohme LLC

A study comparing BNT113 combined with pembrolizumab versus pembrolizumab alone for patients with HPV16-positive head and neck cancer that cannot be removed by surgery

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:BioNTech SE

A study testing NNC0194-0499, cagrilintide, and semaglutide alone or combined to treat liver damage in people with alcohol-related liver disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

A Study of ALN-6400 Safety and Effectiveness in Adults with Hereditary Hemorrhagic Telangiectasia

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pexamsiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Chronic kidney disease+1

Not recruiting

A study of ziltivekimab compared to placebo in people with heart and blood vessel disease, chronic kidney disease and inflammation

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Dermatitis atopic

Not recruiting

Study of Rocatinlimab with Topical Treatments for Adults with Moderate to Severe Atopic Dermatitis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Rocatinlimab
  • Sponsor:Amgen Inc.

Comparing liquid versus capsule forms of phosphatidylcholine in patients with alcoholic liver disease, chronic hepatitis B, and metabolic liver disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Phosphatidyl choline
  • Sponsor:Opella Healthcare Group S.A.S.

Comparing weekly insulin icodec and daily insulin glargine with insulin aspart in adults with type 1 diabetes: a 26-week study of blood sugar control

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Insulin Glargine
  • Sponsor:Novo Nordisk A/S

Arteriosclerosis

Not recruiting

Long-term safety study of pelacarsen in patients with atherosclerotic cardiovascular disease who completed the Lp(a)HORIZON trial

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pelacarsen
  • Sponsor:Novartis Pharma AG

Adenocarcinoma gastric+3

Not recruiting

Study of zolbetuximab, pembrolizumab and chemotherapy in adults with HER2-negative, Claudin 18.

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Astellas Pharma Global Development Inc.

Hidradenitis

Not recruiting

Study of ruxolitinib cream applied to the skin for people with hidradenitis suppurativa

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Incyte Corp.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in St. Ingbert

What the registry says about research in the country

01 Cardiovascular Diseases

In St. Ingbert-Oberwürzbach, clinical research in cardiovascular diseases is focused on reducing heart-related risk and improving long-term outcomes for people with atherosclerotic cardiovascular disease and broader cardiovascular disease concerns.

  • Studies on protecting against major cardiovascular events such as heart attack and stroke
  • Research evaluating whether new treatments can lower cardiovascular risk alongside standard care
  • Trials examining cholesterol control in people with established heart and blood vessel disease

These trials aim to test whether newer therapies can improve prevention and treatment effectiveness in everyday care.

02 Nutritional and Metabolic Diseases

A second major research area is nutritional and metabolic diseases, with a strong emphasis on obesity, overweight, and type 2 diabetes.

  • Weight management studies for people living with obesity or excess body weight
  • Trials combining diabetes care with efforts to support healthier weight outcomes
  • Research looking at better approaches for long-term metabolic control

The overall goal is to explore treatments that can help people lose weight, maintain results, and reduce related health risks.

03 Diabetes and Glycaemic Control

Several studies are centered on diabetes, including type 1 diabetes and type 2 diabetes mellitus, with attention to improving blood sugar control and related complications.

  • Trials comparing new insulin strategies for people with type 1 diabetes
  • Research on glucose-lowering treatments for patients with type 2 diabetes and cardiovascular risk
  • Studies assessing the broader impact of diabetes therapies on long-term health

This work is designed to see whether newer treatment approaches can offer better control and support safer diabetes management.

04 Obesity and Weight Management

A large share of the local trial activity involves obesity and chronic weight management, reflecting strong interest in therapies that support meaningful and lasting weight reduction.

  • Studies testing new medicines for adults with obesity or overweight
  • Research focused on maintaining weight loss over time
  • Trials examining how weight reduction may also improve related metabolic health

These studies are intended to better understand how treatment can support healthier body weight and reduce associated complications.

05 Lipid Lowering and Cardiometabolic Risk

Some trials in Germany are investigating whether newer lipid-lowering approaches can better manage hypercholesterolemia and lower the risk of future heart problems.

  • Research comparing cholesterol-lowering options in people with cardiovascular disease
  • Studies assessing added benefit alongside standard treatment
  • Trials aimed at improving prevention of heart and vascular events

The focus is on finding more effective ways to reduce harmful cholesterol and protect long-term cardiovascular health.

06 Eye Health in Diabetes

One notable study area examines diabetic retinopathy in people with type 2 diabetes, exploring whether diabetes treatment can influence eye health over time.

  • Safety-focused research on long-term effects for diabetic eye disease
  • Studies using ophthalmic assessments to monitor progression
  • Work aimed at understanding how improved glucose control may affect eye complications

This research supports a better understanding of how diabetes therapies may shape both blood sugar control and vision-related outcomes.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.